🔬 𝗘𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝗸𝗻𝗼𝘄𝘀 𝘁𝗵𝗮𝘁 𝗼𝗻𝗹𝘆 𝗮 𝗳𝗿𝗮𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 𝗺𝗮𝗸𝗲 𝗶𝘁 𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀, 𝗼𝗳𝘁𝗲𝗻 𝗱𝘂𝗲 𝘁𝗼 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘀𝘁𝗮𝗴𝗲. The key to success is 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝘁𝗮𝗿𝗴𝗲𝘁 and working with a team that can expertly manage every step to identify a compound that 𝗰𝗮𝗻 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝘁𝗼 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲 𝗻𝗼𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻. At IRBM our strength lies in our end-to-end approach, bringing together an exceptionally talented team of 60+ medicinal and peptide chemists co-located with target biology and pharmacology experts, all under one roof. With decades of experience in 𝘀𝗺𝗮𝗹𝗹 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀 and over 35 years of work in 𝗽𝗲𝗽𝘁𝗶𝗱𝗲𝘀, we are uniquely equipped to support your discovery program, ensuring your compound is thoroughly validated and poised for success as it approaches the pre-IND stage. We’re excited to bring this expertise to the 𝗫𝗫𝗩𝗜𝗜𝗜 𝗘𝗙𝗠𝗖 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹 𝗖𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 from September 1-5, 2024, in Rome, Italy. Our experts, including Alessia Petrocchi, Danila Branca, and Laura Mangiardi, will share insights on SHP2 inhibitors, peptide-based therapeutics, and compound management strategies. 🌟 A special mention goes to the 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗕𝗮𝗻𝗾𝘂𝗲𝘁 𝗼𝗻 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 4, at Villa Miani. This beautiful venue, offering stunning views of the eternal city, is the perfect setting for meaningful discussions about science and innovation. We’re excited to connect with fellow experts and celebrate the future of medicinal chemistry. 🔔 Stay tuned for more updates! #MedicinalChemistry #EFMCISMC2024 #DrugDiscovery #IRBM #ScientificResearch
Questo contenuto non è disponibile qui
Accedi a questo contenuto e molto altro nell’app LinkedIn